Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Drug repurposing in HER2+ breast cancer

Erica Michelle Stringer-Reasor, MD, University of Alabama at Birmingham, Birmingham, AL, explores the repurposing of treatments for HER2-positive breast cancer that are not FDA-approved for the subtype of breast cancer. Resistance to current HER2-positive breast cancer treatments has led to the need for developing novel therapies, with the repurposing of existing breast cancer treatments not specifically approved for HER2-positive breast cancer. One such trial is the ongoing Phase I/IIb trial (NCT03368729) of niraparib, a PARP inhibitor, in combination with trastuzumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.